Visualizing Ligand Binding to a GPCR In Vivo Using NanoBRET

Summary: The therapeutic action of a drug depends on its ability to engage with its molecular target in vivo. However, current drug discovery strategies quantify drug levels within organs rather than determining the binding of drugs directly to their specific molecular targets in vivo. This is a par...

Full description

Bibliographic Details
Main Authors: Diana C. Alcobia, Alexandra I. Ziegler, Alexander Kondrashov, Eleonora Comeo, Sarah Mistry, Barrie Kellam, Aeson Chang, Jeanette Woolard, Stephen J. Hill, Erica K. Sloan
Format: Article
Language:English
Published: Elsevier 2018-08-01
Series:iScience
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004218301184
Description
Summary:Summary: The therapeutic action of a drug depends on its ability to engage with its molecular target in vivo. However, current drug discovery strategies quantify drug levels within organs rather than determining the binding of drugs directly to their specific molecular targets in vivo. This is a particular problem for assessing the therapeutic potential of drugs that target malignant tumors where access and binding may be impaired by disrupted vasculature and local hypoxia. Here we have used triple-negative human breast cancer cells expressing β2-adrenoceptors tagged with the bioluminescence protein NanoLuc to provide a bioluminescence resonance energy transfer approach to directly quantify ligand binding to a G protein-coupled receptor in vivo using a mouse model of breast cancer. : Biological Sciences Tools; Cancer; Molecular Interaction; Optical Imaging Subject Areas: Biological Sciences Tools, Cancer, Molecular Interaction, Optical Imaging
ISSN:2589-0042